Posted by Michael Wonder on 17 Mar 2021
European Commission approves expanded indication for Merck’s Keytruda (pembrolizumab) in adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma
17 March 2021 - First Pediatric Indication for KEYTRUDA in the European Union.
Merck today announced that the European Commission has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.
